Immune cell changes detected in Waldenstrom macroglobulinemia (WM)
A new study has found mutations originating in blood progenitor cells, possibly leading to Waldenstrom macroglobulinemia (WM) therapies.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A new study has found mutations originating in blood progenitor cells, possibly leading to Waldenstrom macroglobulinemia (WM) therapies.
A potential drug to treat a subset of gastrointestinal stroma tumours (GIST) have been found to tackle intestinal tract cancer.
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
A new study has identified a vital enzyme, known as APOBEC3A, that could lead to new treatments against cancers and viral infections.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
Frameshifting therapy has been shown to reduce the number of mast cells by “mutating” mRNA, showing promise as a new cancer treatment.
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Scientists have uncovered the crucial role of the enzyme NMNAT-2 in ovarian cancers, as well as other biomarkers that could lead to treatments.
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.